Twist Bioscience (TWST) Net Income towards Common Stockholders (2017 - 2026)
Twist Bioscience (TWST) has 10 years of Net Income towards Common Stockholders data on record, last reported at -$44.0 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 11.86% to -$44.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$81.3 million, a 57.49% increase, with the full-year FY2025 number at -$77.7 million, up 62.8% from a year prior.
- Net Income towards Common Stockholders reached -$44.0 million in Q1 2026 per TWST's latest filing, down from -$30.5 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for TWST hit a ceiling of $20.4 million in Q2 2025 and a floor of -$85.6 million in Q2 2024.
- A 5-year average of -$43.4 million and a median of -$44.0 million in 2026 define the central range for Net Income towards Common Stockholders.
- Peak YoY movement for Net Income towards Common Stockholders: crashed 59.99% in 2022, then skyrocketed 123.82% in 2025.
- Tracing TWST's Net Income towards Common Stockholders over 5 years: stood at -$41.8 million in 2022, then fell by 2.83% to -$43.0 million in 2023, then grew by 26.53% to -$31.6 million in 2024, then increased by 3.45% to -$30.5 million in 2025, then plummeted by 44.3% to -$44.0 million in 2026.
- Business Quant data shows Net Income towards Common Stockholders for TWST at -$44.0 million in Q1 2026, -$30.5 million in Q4 2025, and -$27.1 million in Q3 2025.